hVIVO continues to push the boundaries of infectious disease research with the successful completion of its pilot human metapneumovirus (hMPV) characterisation study. This milestone, highlighted by the company’s Chief Scientific Officer, showcases hVIVO’s ability to deliver impactful insights into respiratory illnesses. The study demonstrated a robust infectivity rate and reliably induced symptomatic disease in healthy volunteers, underscoring its potential for future clinical trials and vaccine development.
This successful pilot study not only reinforces hVIVO’s expertise in virology and human challenge trials but also provides a vital step forward in addressing the unmet need for effective treatments and prevention strategies for hMPV. With its proven ability to induce consistent symptomatic responses in volunteers, the study positions hVIVO at the forefront of advancing understanding and therapeutic solutions for this significant respiratory pathogen.
hVIVO plc (formerly Open Orphan plc), led by Cathal Friel, is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials, providing end-to-end early clinical development services for its broad and long-standing client base of biopharma companies.
